Drug intelligence / Profile preview

Nanite HIV gene therapy

Development stage: Preclinical
Lead developer: Nanite
Modality: Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

Nanite Therapeutics is developing a non-viral gene therapy for HIV using its proprietary SAYER™ platform. The platform utilizes AI-driven design to create tissue-specific polymer nanoparticles (PNPs) for the delivery of DNA-encoded therapeutics. This specific program delivers DNA that encodes for therapeutic antibodies, enabling durable *in vivo* production of these antibodies to treat or prevent HIV. The project is intended to provide a transformative treatment option, particularly for populations with limited access to medical care. It is supported by a $1.8M grant from the Bill & Melinda Gates Foundation and is currently in preclinical development.

Other names: Nanite PNP HIV programNanite Gates Foundation HIV program

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on Nanite HIV gene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanite HIV gene therapy.